Paragon 28
4B Inverness Court
Suite 280
Englewood
Colorado
80112
Tel: 888-728-1888
Fax: 888-728-1220
Website: http://www.paragon28.com/
About Paragon 28
Paragon 28 Inc. was established in 2010 to address the unmet and under-served needs of the foot and ankle community. From the onset, Paragon 28 has made it our goal to re-invent the space of foot and ankle surgery. We believe that through research and innovation we can create new and improved solutions to the challenges faced by foot and ankle specialists.YEAR FOUNDED:
2010
LEADERSHIP:
Founder and CEO: Albert DaCosta
JOBS:
Please click here for Paragon 28 job opportunities.
PRODUCTS:
All Products
91 articles about Paragon 28
-
Paragon 28 Reports Fourth Quarter and Full Year 2023 Financial Results and Provides 2024 Net Revenue Guidance
2/29/2024
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter and year ended December 31, 2023 and provided 2024 Net Revenue guidance.
-
Paragon 28 To Report Fourth Quarter and Full Year 2023 Financial Results on February 29, 2024
2/6/2024
Paragon 28, Inc. announced it will report financial results for the fourth quarter and full year 2023 after market close on Thursday, February 29, 2024.
-
Paragon 28 Launches PRECISION® MIS Bunion System Offering Surgeons a Guided Minimally Invasive Surgical Solution for Treating Patients with Bunions
2/1/2024
Paragon 28, Inc. (NYSE: FNA) is pleased to announce the launch of the PRECISION® MIS Bunion System, which allows surgeons to complete a distal metatarsal osteotomy using a minimally invasive (MIS) surgical technique.
-
Paragon 28 Announces the Launch of the FJ2000™ Power Console and Burr System Designed Specifically for Foot and Ankle Procedures
1/30/2024
Paragon 28, Inc. is proud to announce a novel solution in modernizing foot and ankle surgery with the launch of its FJ2000™ Power Console and Burr System designed for a wide range of minimally invasive and open procedures in the foot and ankle.
-
Paragon 28 Launches the Mister Tendon™ Harvester System – The First and Only Minimally Invasive Harvesting System for FHL and FDL Tendon Transfer Procedures
1/26/2024
Paragon 28, Inc. (NYSE: FNA), is pleased to announce the launch of the Mister Tendon™ System which allows surgeons to perform a distal cut of the flexor hallucis longus (“FHL”) or flexor digitorum longus (“FDL”) tendon through a minimally invasive incision, harvesting a working length of tendon suitable for tendon transfer procedures.
-
Paragon 28 Announces First Cases and Limited Market Release of the Bun-Yo-Matic™ – A Next Generation Clamp and Cut Guide System for Lapidus Bunion Procedures
1/17/2024
Paragon 28, Inc. (NYSE: FNA), is excited to announce the limited market release of its Bun-Yo-Matic™ Lapidus Clamp System and completion of the first surgical cases in Orange County, California and Seattle, Washington.
-
Paragon 28 Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023
1/8/2024
Paragon 28, Inc. today announced a range of its preliminary unaudited net revenue for the fourth quarter and full year ended December 31, 2023.
-
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler® Knotless Anchor System and Innovative Bridgeline™ Tape
1/5/2024
Paragon 28 Advances Foot and Ankle Specific Soft Tissue Portfolio with Launch of Grappler ® Knotless Anchor System and Innovative Bridgeline™ Tape.
-
Paragon 28 Launches BEAST™ Cortical Fibers Expanding its Biologics Portfolio
11/14/2023
Paragon 28, Inc. is pleased to announce the launch of its BEAST™ Cortical Fibers which provide an osteoinductive porous structure for cellular attachment and an osteoinductive potential to aid in cellular differentiation and bone formation.
-
Paragon 28 Reports Third Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
11/7/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended September 30, 2023 and reaffirmed its 2023 net revenue guidance.
-
Paragon 28 Announces New $150 Million Credit Facility Replacing Existing $90 Million Credit Facility
11/7/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced that it has received a new $150 million credit facility from Ares Capital Corporation to replace its existing $90 million senior credit facility.
-
Paragon 28 to Present at Upcoming November 2023 Investor Conferences
11/3/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will be presenting in fireside chats at two upcoming investor conferences.
-
Paragon 28 To Report Third Quarter Financial Results on November 7, 2023
10/17/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the third quarter 2023 after market close on Tuesday, November 7, 2023.
-
Paragon 28 to Present at the Morgan Stanley 21st Annual Global Healthcare Conference
8/28/2023
Paragon 28, Inc. (NYSE: FNA), a leading medical device company exclusively focused on the foot and ankle orthopedic market, today announced that Albert DaCosta, Chairman and CEO and Steve Deitsch, CFO will participate in a fireside chat at the Morgan Stanley 21st Annual Global Healthcare Conference on Monday, September 11, 2023, at 4:55 p.m. Eastern Time / 2:55 p.m. Mountain Time.
-
Paragon 28 Reports Second Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
8/2/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended June 30, 2023 and reaffirmed its 2023 net revenue guidance.
-
Paragon 28 to Present at the Canaccord Genuity 43rd Annual Growth Conference
7/28/2023
Paragon 28, Inc. today announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Canaccord Genuity 43rd Annual Growth Conference on Wednesday, August 9, 2023, at 8:30 a.m. Eastern Time / 6:30 a.m. Mountain.
-
Paragon 28 To Report Second Quarter Financial Results on August 2, 2023
7/12/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, announced it will report financial results for the second quarter 2023 after market close on Wednesday, August 2, 2023.
-
Paragon 28 Launches Comprehensive Supramalleolar Osteotomy System
5/23/2023
Paragon 28, Inc. is pleased to announce the launch of its Gorilla® Supramalleolar Osteotomy Plating and PRESERVE™ SMO Allograft System which were developed to provide surgeons versatility in plate selection and surgical approach for supramalleolar osteotomies.
-
Paragon 28 Reports First Quarter 2023 Financial Results and Reaffirms 2023 Net Revenue Guidance
5/4/2023
Paragon 28, Inc., a leading medical device company exclusively focused on the foot and ankle orthopedic market, reported financial results for the quarter ended March 31, 2023 and reaffirmed its 2023 net revenue guidance.
-
Paragon 28 to Present at the Bank of America Securities 2023 Healthcare Conference
4/26/2023
Paragon 28, Inc. announced that Albert DaCosta, Chairman and CEO, and Steve Deitsch, CFO, will participate in a fireside chat at the Bank of America Securities 2023 Healthcare Conference on Wednesday, May 10, 2023, at 5:20 p.m. Eastern Time / 3:20 p.m. Mountain Time.